Nasus Pharma Ltd. (NSRX)
:NSRX
Epinephrine 4Mg Nasal Powder Spray, Adrenalin 0.5Mg Injectable Product
Anaphylaxis Food
Phase II/III
Enrolling By Invitation
FMXIN002 in Patients at Risk of Anaphylaxis
Jun 08, 2025
―
A: Epinephrine Injection, B: Fmxin002 3.6Mg, C: Fmxin002 4.0Mg
Anaphylaxis, Anaphylactic Reaction
Phase I/II
Completed
Comparative Bioavailability of Intranasal Epinephrine
Dec 18, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nasus Pharma Ltd. (NSRX) have in its pipeline
NSRX is currently developing the following drugs: Epinephrine 4Mg Nasal Powder Spray, Adrenalin 0.5Mg Injectable Product, A: Epinephrine Injection, B: Fmxin002 3.6Mg, C: Fmxin002 4.0Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.